A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)
Latest Information Update: 26 Jul 2024
At a glance
- Drugs CAL 02 (Primary) ; Antibacterials
- Indications Community-acquired pneumonia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Eagle Pharmaceuticals
- 11 Sep 2023 According to an Eagle Pharmaceuticals media release, the company anticipates of having its 50% interim report around the first half of 2024.
- 11 Sep 2023 According to an Eagle Pharmaceuticals media release, the trial in-progress of this study will be presented at the conference co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID).
- 24 Jul 2023 According to an Eagle Pharmaceuticals media release, the first patient has been randomized in this trial.The Company expects to have approximately 50 sites up and running by the end of September, with 100 sites up by year-end in readiness for the global pneumonia season. In addition, depending upon recruitment rates, Eagle anticipates having its first 50% interim report around the first quarter of 2024.